Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BRCA1-A complex subunit RAP80 (abbreviated as RAP80; gene: UIMC1) is a nuclear adaptor protein characterized by two N-terminal ubiquitin-interacting motifs (UIMs)[1][3]. RAP80 is a core component of the BRCA1-A complex, which also includes BRCC36, BRE, and MERIT40[4]. RAP80 recognizes Lys63-linked polyubiquitin chains at DNA double-strand break sites through its UIM domains, facilitating recruitment of the BRCA1-A complex to DNA damage-induced nuclear foci[5][6]. This process enables BRCA1 localization to sites of DNA damage for error-free homologous recombination (HR) repair but also plays a regulatory role in limiting BRCA1's recombination activity, likely shifting the balance between HR and non-homologous end joining (NHEJ)[2][3][4]. Loss or mutation of RAP80 impairs the recruitment of BRCA1 and associates with increased genomic instability, defective DNA repair, and cancer predisposition[1][2][4]. RAP80 itself is not a direct therapeutic target or traditional receptor/enzyme; rather, its role is as an essential mediator of genome maintenance and a potential indirect influencer in cancer etiology and therapy sensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BRCA1-A complex subunit RAP80 (RAP80).